Businesses
Here's a look at documents from U.S. and international businesses
Featured Stories
ViiV Healthcare Presents Pipeline Data for Two Investigational HIV Treatment Therapies With Potential for Twice-Yearly Dosing
LONDON, England, Feb. 26 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:
* * *
ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing
- VH184, the first, third generation integrase inhibitor in development shows potential for up to twice-yearly dosing intervals
- Additional in-vitro data on VH184 demonstrate improved potency and an enhanced resistance profile versus bictegravir
- VH499 demonstrates good tolerability, supporting twice-yearly dosing intervals
*
GSK plc
... Show Full Article
LONDON, England, Feb. 26 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:
* * *
ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing
- VH184, the first, third generation integrase inhibitor in development shows potential for up to twice-yearly dosing intervals
- Additional in-vitro data on VH184 demonstrate improved potency and an enhanced resistance profile versus bictegravir
- VH499 demonstrates good tolerability, supporting twice-yearly dosing intervals
*
GSK plc(LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,/* today announced data from its phase 1 study of long-acting formulations of VH184, the first, third-generation integrase strand transfer inhibitor (INSTI) in development for HIV./1 Results show a single-dose injection could maintain drug levels for up to six months. In-vitro data from a separate study demonstrate improved potency and an enhanced resistance profile versus bictegravir in resistant HIV strains./2
Additional data from ViiV Healthcare's long-acting pipeline presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, Colorado, show VH499, an investigational capsid inhibitor, was generally well tolerated and support the potential for ultra long-acting (ULA) twice-yearly dosing./3 These early-stage findings, alongside continued progress of other ULA pipeline assets, including lotivibart (N6LS), reinforce ViiV Healthcare's commitment to advancing innovative long-acting HIV therapies that reduce the need for daily treatment and expand options for people living with HIV.
Kimberly Smith, M.D., MPH, Head of Research & Development at ViiV Healthcare, said: "Our R&D efforts are built around delivering best-in-class, long-acting therapies that challenge the status quo and help make HIV treatment a smaller, less frequent part of people's lives. The data we're presenting on VH184, our third-generation INSTI, indicate a potential high barrier to resistance and twice-yearly dosing intervals. Early results for VH499, a capsid inhibitor, point to its potential for dosing every six months. These data underscore how ViiV Healthcare is working to define the future of HIV care through ultra long-acting options designed to address the needs and preferences of people living with HIV and will inform our plans to introduce the first INSTI-based, twice-yearly regimen for people with HIV."
VH184 shows potential for dosing intervals of up to twice-yearly and improved activity versus bictegravir.1,2 In a phase 1 study of long-acting formulations in adults without HIV, VH184 was given as a single subcutaneous (SC) or intramuscular (IM) injection in one of two formulations. Both formulations demonstrated long-acting properties, with one maintaining steady drug levels through Month 7, indicating the potential for twice-yearly dosing.
The VH184 formulations were generally well tolerated, with most side effects limited to mild grade 1 injection site reactions (ISRs) such as erythema, pain, and nodules, with fewer grade 2 and grade 3 ISRs. The safety profile of VH184 is consistent with previous studies and is similar to that of approved INSTIs.
In an in-vitro study also presented at CROI, VH184 demonstrated an improved virology profile, specifically an enhanced resistance profile compared with bictegravir, when evaluated against HIV with mutations linked to resistance to second generation INSTIs. VH184 retained activity against a broad range of resistant virus strains, including those with multiple INSTI associated substitutions, indicating a potential higher barrier to resistance.
Together, these results confirm VH184 as a third-generation INSTI with long-acting potential and extended coverage of viruses with INSTI resistance mutations. Phase 2b studies will further determine optimal dosing schedules and continue to assess its potential as a twice-yearly treatment for people living with HIV.
VH499 shows potential for twice-yearly dosing.3 In an ongoing phase 1 study in adults without HIV, VH499 was given as a single IM or SC injection between 100mg and 1200mg. Both injection routes maintained stable drug levels for a prolonged period, indicating that injectable VH499 has the potential for ULA dosing intervals up to six months.
VH499 was generally well tolerated, with most common side effects being injection site reactions, most frequently injection site pain at grade 1 or 2, with the majority mild to moderate in severity and short-lived. There were no serious adverse events (AE) and no study withdrawals due to AEs.
Further studies will use these data to optimise dosing schedules for VH499. These findings build on proof-of-concept data previously presented at CROI 2025 and add to the growing body of evidence for VH184 and VH499 as potential components of future ULA treatment regimens.
* * *
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. Shionogi became a ViiV shareholder in October 2012. The company's aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.
For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com.
* * *
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
* * *
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q4 Results for 2025.
* * *
*On 20 January 2026, GSK plc and Shionogi & Co., Ltd announced that they have reached agreement together with Pfizer Inc. for the economic interest in ViiV Healthcare Limited currently held by Pfizer to be replaced with an investment by Shionogi. Completion of the transaction is subject to certain regulatory clearances in relevant markets, and is expected to occur during the first quarter of 2026.
* * *
References
1./ H. Back et al. Pharmacokinetics and Evaluation of Potential Dosing Regimens for Long-Acting VH4524184. Presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026.
2./ M. Underwood et al. Third-Generation INSTI VH4524184 (VH-184) Has an Enhanced Resistance Profile vs Bictegravir. Presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026.
3./ N. Thakkar et al. Injectable HIV-1 Capsid Inhibitor VH4011499 (VH-499) Formulation Supports Ultra-Long-Acting Dosing. Presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026.
* * *
Original text here: https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-pipeline-data-for-two-investigational-hiv-treatment-therapies-with-potential-for-twice-yearly-dosing/
[Category: BizPharmaceuticals]
Skin Cancer Foundation and AccuWeather Announce Partnership to Strengthen Public Understanding of the UV Index
STATE COLLEGE, Pennsylvania, Feb. 26 -- AccuWeather, a provider of commercial weather forecasting services, issued the following news release on Feb. 25, 2026:
* * *
The Skin Cancer Foundation and AccuWeather(R) Announce Partnership to Strengthen Public Understanding of the UV Index
The Foundation adds AccuWeather's Daily Max UV Index to its website as partners join forces to share informational content regarding UV exposure and skin cancer.
*
The Skin Cancer Foundation and AccuWeather today announced a new partnership to improve public understanding of ultraviolet (UV) radiation, the leading
... Show Full Article
STATE COLLEGE, Pennsylvania, Feb. 26 -- AccuWeather, a provider of commercial weather forecasting services, issued the following news release on Feb. 25, 2026:
* * *
The Skin Cancer Foundation and AccuWeather(R) Announce Partnership to Strengthen Public Understanding of the UV Index
The Foundation adds AccuWeather's Daily Max UV Index to its website as partners join forces to share informational content regarding UV exposure and skin cancer.
*
The Skin Cancer Foundation and AccuWeather today announced a new partnership to improve public understanding of ultraviolet (UV) radiation, the leadingcause of skin cancer. By combining AccuWeather's proven Superior Accuracy(TM) with The Skin Cancer Foundation's evidence-based guidance on UV safety, the partners aim to "take back the UV index" and ensure that people have access to clear, consistent, science-driven information daily. As part of this initiative, The Skin Cancer Foundation will feature the AccuWeather Daily Max UV Index on relevant pages of its website. The collaboration comes at a time of rising misinformation about UV exposure and mixed public understanding of how the UV Index works.
For video interviews and other assets please see our Digital Media Kit.
"Skin cancer prevention starts with awareness," says Deborah S. Sarnoff, MD, president of The Skin Cancer Foundation. "The UV Index is a simple and powerful tool that the public can use to understand this invisible threat that is the cause of 90 percent of skin cancers. Partnering with AccuWeather on this initiative ensures that this lifesaving information reaches people where they go every day to prepare themselves for their time outdoors. We want to remind the public to take that extra step of protecting themselves from these UV rays, so that they can dramatically lower their risk for developing skin cancer."
In addition to leveraging its media platform that reaches billions to promote UV education and skin cancer awareness, AccuWeather's Daily Max UV Index provides easy-to-read risk categories and localized hourly UV forecasts.
"AccuWeather provides hour-by-hour UV index forecasts with the greatest accuracy and detail available from any source. These highly localized UV indices and forecasts provide enhanced protection from excessive UV exposure by allowing users to track their UV exposure hour-by-hour, down to the tenths of a unit," said Dr. Joel N. Myers, AccuWeather Founder and Executive Chair. "This contributes to a healthier, more informed, and more comfortable lifestyle. Through our partnership with The Skin Cancer Foundation, our goal is to significantly reduce cases of melanoma and skin cancer fatalities in the United States and around the world."
While UV education and awareness are important, The Skin Cancer Foundation would like to remind the public that sun protection is necessary regardless of the daily UV index rating and recommends that people heed the following recommendations to protect themselves against sun exposure at all times:
Clothing is a strong line of defense. Wear clothing with a minimum UPF factor of 50, a wide-brimmed hat and UV-blocking sunglasses.
Apply sunscreen to all exposed skin, even on days when the UV index is low. Use a broad-spectrum sunscreen with a minimum SPF of 30 for daily use and an SPF 50 or higher when engaging in outdoor activities. Reapply at least every two hours or after sweating.
Seek the shade during peak hours (10 AM to 4 PM) or when the UV index is high.
Skin cancer is currently the most common cancer in the United States, with more than 5 million cases diagnosed each year. UV exposure is the leading preventable cause for these cancers. Both organizations emphasize that strengthening public knowledge is critical to reducing these numbers, and empowering people with real-time, trustworthy UV information is a key step forward. This partnership marks a significant expansion of The Skin Cancer Foundation's mission to promote sun safety and AccuWeather's commitment to helping people make the best weather impacted decisions. For more information, visit SkinCancer.org and AccuWeather.com.
* * *
About The Skin Cancer Foundation
The Skin Cancer Foundation (SCF), a 501(c)(3) nonprofit organization, saves and improves lives by empowering people to take a proactive approach to daily sun protection and the early detection and treatment of skin cancer. The Foundation delivers public education programs, provides patients with guidance and reassurance, engages medical professionals, awards research grants and leads advocacy campaigns that call for policy changes. As a service to consumers, SCF grants its industry-recognized Seal of Recommendation to products that meet its criteria for safe and effective sun protection. SCF also operates Destination Healthy Skin, a program that works with local dermatologists in communities around the U.S. to provide free skin cancer screenings to those in need. Since its inception in 1979, the Foundation has recommended regular skin exams and following a complete sun protection strategy that includes seeking shade, using sunscreen daily and covering up with clothing, hats and sunglasses. SkinCancer.org.
* * *
About AccuWeather, Inc. and AccuWeather.com
AccuWeather, recognized and documented as the most accurate and most used source of weather forecasts and warnings in the world, has saved over 12,000 lives, prevented injury to over 100,000 people, and saved companies tens of billions of dollars through better planning and decision-making.
A billion people around the world rely on AccuWeather's proven Superior Accuracy(TM) across our consumer digital platforms. AccuWeather.com is the #1 weather destination and one of the top 100 most-visited websites in the world, and our award-winning AccuWeather app delivers detailed real-time forecasts to millions of smartphones.
AccuWeather forecasts also appear on digital signage, in 700 newspapers, are heard on over 400 radio stations, and viewed on 100 television stations. The AccuWeather Network and AccuWeather NOW(R) reach an audience of over 125 million on cable and streaming platforms.
AccuWeather For Business serves more than half of the Fortune 500 companies and thousands of other businesses and government agencies globally who pay for the most accurate weather forecasts than from any other source.
Visit AccuWeather.com for the most accurate hyperlocal forecasts, weather news, and information, and download the free AccuWeather app for Android or iOS.
* * *
Original text here: https://www.accuweather.com/en/press/the-skin-cancer-foundation-and-accuweather-announce-partnership-to-strengthen-public-understanding-of-the-uv-index/1867278
[Category: BizTravel]
Las Vegas Local Hits $107,798 Jackpot at Suncoast Hotel & Casino
LAS VEGAS, Nevada, Feb. 26 -- Boyd Gaming issued the following news release on Feb. 25, 2026:
* * *
Las Vegas Local Hits $107,798 Jackpot at Suncoast Hotel & Casino
A local guest hit it big at Suncoast Hotel & Casino on Saturday, February 21, winning a thrilling jackpot worth $107,798.
At approximately 8:21 p.m., the guest placed a $5 bet on a Dragon Cash(TM) slot game by Aristocrat Gaming(TM) and landed the extraordinary win.
Suncoast Hotel & Casino features a 95,000-square-foot casino floor, a 406-seat bingo room, and a 16-screen movie theater, offering guests a dynamic mix of gaming and
... Show Full Article
LAS VEGAS, Nevada, Feb. 26 -- Boyd Gaming issued the following news release on Feb. 25, 2026:
* * *
Las Vegas Local Hits $107,798 Jackpot at Suncoast Hotel & Casino
A local guest hit it big at Suncoast Hotel & Casino on Saturday, February 21, winning a thrilling jackpot worth $107,798.
At approximately 8:21 p.m., the guest placed a $5 bet on a Dragon Cash(TM) slot game by Aristocrat Gaming(TM) and landed the extraordinary win.
Suncoast Hotel & Casino features a 95,000-square-foot casino floor, a 406-seat bingo room, and a 16-screen movie theater, offering guests a dynamic mix of gaming andentertainment experiences.
For more information, visit www.suncoast.boydgaming.com.
* * *
About Suncoast Hotel and Casino
Located at the corner of Alta Drive and South Rampart Boulevard, Suncoast Hotel and Casino is a property of Boyd Gaming Corporation, the Official and Exclusive Local Casinos of the Las Vegas Raiders. Suncoast features six restaurants, a 16-screen movie theater, a 406-seat bingo room and a 95,000-square-foot casino. For more information, visit www.suncoastcasino.com and connect on Facebook, Twitter and Instagram.
Founded in 1975, Boyd Gaming Corporation is a leading geographically diversified operator of 27 gaming entertainment properties in 11 states. The Company also manages a tribal casino in northern California, and owns and operates Boyd Interactive, a B2B and B2C online casino gaming business. Boyd Gaming's nationwide portfolio is connected through Boyd Rewards, recognized as the nation's favorite casino loyalty program by readers of USA Today. Named by Forbes magazine as one of "America's Best Companies," and led by one of the most experienced teams in the industry, Boyd Gaming is dedicated to delivering an outstanding entertainment experience and memorable guest service. For additional Company information and press releases, visit https://www.boydgaming.com.
* * *
Original text here: https://media.boydgaming.com/SuncoastFebJackpot
[Category: BizEntertainment Industry]
How NPS and HCAHPS Work Together to Transform Patient Experience
LINCOLN, Nebraska, Feb. 26 (TNSrep) -- NRC Health, a provider of customer intelligence in healthcare, issued the following news:
* * *
How NPS and HCAHPS Work Together to Transform Patient Experience
As health systems increasingly rely on patient feedback to guide improvement strategies, many face a familiar challenge: their real time patient feedback doesn't always line up with their HCAHPS results. This discrepancy can lead to confusion, stalled progress, and even financial risk.
Building on data and strategy from NRC Health's latest nSight, a recent webcast takes a deeper dive into how
... Show Full Article
LINCOLN, Nebraska, Feb. 26 (TNSrep) -- NRC Health, a provider of customer intelligence in healthcare, issued the following news:
* * *
How NPS and HCAHPS Work Together to Transform Patient Experience
As health systems increasingly rely on patient feedback to guide improvement strategies, many face a familiar challenge: their real time patient feedback doesn't always line up with their HCAHPS results. This discrepancy can lead to confusion, stalled progress, and even financial risk.
Building on data and strategy from NRC Health's latest nSight, a recent webcast takes a deeper dive into howNet Promoter Score (NPS) and HCAHPS can, and should, work together. Sarah Fryda, M.S., Research Team Manager, and Jason Messerli, Strategic Advisor for Customer Strategy walked through the correlation between the two measures, the pitfalls of relying on short-term data, and why timely and representative feedback is essential for improving both patient experience and outcomes.
If your organization is striving to make sense of patient experience data and drive meaningful improvement, this webcast delivered practical insights and evidence backed strategies. Watch the full session on demand for the complete discussion.
Why NPS and HCAHPS Are More Connected Than They Appear
Many health systems wrestle with what Fryda described as "conflicting stories" between real time patient feedback and HCAHPS scores. But according to the NRC Health research team, these metrics aren't contradictory at all, they are deeply connected.
"We know that NPS and HCAHPS are strongly related," shared Fryda. "And we can actually predict what future CMS HCAHPS scores will be."
Using longitudinal data, NRC Health has found that hospitals performing well on HCAHPS typically perform well on NPS, and vice versa. Even when the metrics diverge in the short term, long-term patterns show strong alignment across every major HCAHPS dimension.
This is critical because organizations sometimes treat the two measures as separate or even competing. Fryda emphasized that they "actually do support each other," and failing to effectively use one can lead to missed insights and missed revenue.
The bottom line: NPS captures immediate patient perceptions, while HCAHPS reflects whether positive behaviors are consistently applied over time. Together, they paint a fuller, more actionable picture of experience.
How Short Term Data Can Mislead
Many health systems feel pressure to evaluate patient experience on a month by month basis. But as Messerli cautioned, this is one of the most common and damaging mistakes organizations make.
Short-term fluctuations often disguise true performance, causing leaders to question their approach or pivot strategies prematurely.
Messerli recalled a recent conversation with a CMO. "I showed him a year over year trend where they improved every single year for five years," he recalled, "and he said, 'I had no idea we were improving like this.'"
This experience highlights a widespread issue: organizations become so focused on monthly peaks and dips that they lose sight of steady progress. To address this, Messerli encouraged leaders to rely more heavily on rolling 12 month trends, which provide a clearer view of whether behaviors are truly improving.
"These long term relationships help get rid of some of the noise," said Messerli, "and are much better representations of our performance over time."
By stepping back and viewing performance through a broader lens, leaders can avoid unnecessary shifts in strategy and instead refine what's already working.
The Risks of Ignoring or Misinterpreting Patient Feedback
Fryda discussed the real organizational risks that arise when NPS and HCAHPS are not used together, or when short term data influences decisions too heavily.
These include:
* Analysis paralysis: Teams freeze when metrics don't align perfectly, delaying decisions or avoiding action entirely.
* Overemphasis on HCAHPS: Because HCAHPS is public and tied to reimbursement, many organizations fixate on it at the expense of actionable feedback coming from contemporary channels.
* Financial penalties: Organizations that fail to understand what drives patient experience risk both underperformance and lost revenue opportunities.
"Performance on the HCAHPS survey accounts for one quarter of a hospital's total performance score," said Fryda. "Hospitals can lose or earn back up to 2% of Medicare inpatient payments."
Why Timely and Representative Feedback Drives Better Results
One of the most compelling insights from the webcast centered on the speed and representativeness of feedback.
HCAHPS responses overwhelmingly come from older adults, a demographic that evaluates care differently than younger generations do.
"Roughly 63% of all HCAHPS responses come from those 65 and over," Messerli explained. "And in some cases, I've seen it as high as 80%."
This creates an imbalance that can mask issues experienced by younger or more diverse patients. Modern outreach methods help organizations capture feedback from a broader population, painting a more accurate picture of patient needs and expectations.
Timely feedback also enables:
* Faster coaching and recognition
* More agile improvement cycles
* Early identification of loyalty drivers
* More effective service recovery
Real-time alerts allow teams to intervene early, boost trust, and even strengthen loyalty, sometimes more than if nothing had gone wrong.
How Real Time Feedback Accelerates HCAHPS Improvement
Fryda shared data demonstrating that organizations using real-time feedback consistently and effectively are improving more quickly on HCAHPS.
NRC Health customers saw measurable gains across all 10 HCAHPS dimensions between 2022 and 2024, including Staff Responsiveness, Overall Hospital Rating, and Hospital Quietness.
"Experience performance doesn't just recover, it accelerates," said Fryda.
The reason? When organizations use real-time feedback to reinforce key behaviors, those same behaviors eventually show up in HCAHPS performance.
Strategies for Smaller Hospitals
Not all hospitals have the patient volume to fully leverage real-time feedback in inpatient settings. But smaller organizations still have powerful options.
Fryda recommended focusing on the emergency department, where a large percentage of inpatients begin their care journey. "How they are treated in the ED does impact their experience," she shared. "One way you can really impact HCAHPS is by using real-time feedback to evaluate those emergency department experiences."
Improving the ED experience influences both real-time satisfaction and future HCAHPS responses once patients transition to inpatient care.
Creating a Culture of Service-Minded Leadership
A standout theme from the webcast was the role leadership plays in elevating experience.
"The best way I've seen to create a culture of accountability is to have effective executive leadership rounding from a supportive standpoint," said Messerli.
Executives should round not to evaluate staff performance, but to understand challenges and offer solutions. Messerli described a powerful example:
When leaders are visible, engaged, and supportive, frontline teams feel valued and empowered, fueling better patient interactions and improved outcomes.
Watch the full webcast (https://go.nrchealth.com/webcast/beyond-the-scores) for more insights and download the recent nSight report (https://go.nrchealth.com/nSight/measurement-to-momentum) to dive deeper.
* * *
Original text here: https://nrchealth.com/blog/how-nps-hcahps-tranform-patient-experience/
[Category: BizHealth Care]
Gartner Survey Shows 55% of Supply Chain Leaders Expect Agentic AI to Reduce Entry-Level Hiring Needs
STAMFORD, Connecticut, Feb. 26 (TNSrep) -- Gartner, an information technology research and advisory company, issued the following news release:
* * *
Gartner Survey Shows 55% of Supply Chain Leaders Expect Agentic AI to Reduce Entry-Level Hiring Needs
Analysts to Discuss Agentic AI's Impact on the Future of Supply Chain at Gartner Supply Chain Symposium/Xpo
*
More than half (55%) of supply chain leaders expect that advancements in agentic AI will reduce the need to hire for entry-level positions, while 51% believe the technology will drive a shift to overall workforce reductions, according
... Show Full Article
STAMFORD, Connecticut, Feb. 26 (TNSrep) -- Gartner, an information technology research and advisory company, issued the following news release:
* * *
Gartner Survey Shows 55% of Supply Chain Leaders Expect Agentic AI to Reduce Entry-Level Hiring Needs
Analysts to Discuss Agentic AI's Impact on the Future of Supply Chain at Gartner Supply Chain Symposium/Xpo
*
More than half (55%) of supply chain leaders expect that advancements in agentic AI will reduce the need to hire for entry-level positions, while 51% believe the technology will drive a shift to overall workforce reductions, accordingto Gartner, Inc., a business and technology insights company.
Gartner surveyed 509 supply chain leaders globally across industries from July to October 2025. While the view of agentic AI's ultimate impact on headcount plans remains split, there is wider agreement among respondents (86%) that adoption of agentic AI will require new processes for developing future talent pipelines, signaling a need to rethink how supply chain organizations build skills and utilize talent.
"The highest performing supply chain organizations are using AI to reinvent how work gets done and how talent is developed. They are not treating AI as a blunt instrument for headcount reduction," said Marco Sandrone, VP Analyst in Gartner's Supply Chain practice. "The priority for chief supply chain officers (CSCOs) should be redesigning roles, skills, and workforce processes, so people and machines can create value together."
"Changes in ways of working driven by advancements in AI and agentic AI" was cited as the single most influential driver redefining supply chain strategy over the next two years (see Figure 1).
Figure 1: Top Influential Drivers Redefining Supply Chain Strategy Over the Next Two Years (Sum of Top 3)
Human-Machine Collaboration Strategies
Gartner's survey analysis identified respondents from high-performing organizations that exceeded expectations in areas, such as customer lead time, satisfaction, time to market, revenue growth, and sustainability goals over the past year. Gartner analysts also interviewed 15 supply chain leaders from companies with a consistent presence in the Gartner Supply Chain Top 25, uncovering the strategies and practices driving their success.
These high-performing respondents' adoption of agentic AI was significantly higher than other respondents across procurement, production, logistics, warehouse management, and planning. As a result, the high-performing respondents were more likely to recognize that the traditional talent pyramid will change. While this may reduce the need for traditional entry-level roles, these leaders are prioritizing talent strategy reinvention, rather than headcount reduction.
Over the next two years, these high-performing leaders plan to prioritize the following talent strategies:
* Upskill talent for the AI era
* Use AI-enabled tools to optimize workforce planning and candidate engagement
* Increase automation and advanced technologies to improve efficiency and reduce reliance on manual labor
"Entry-level roles as understood today may fade in importance, but supply chains will still need emerging talent that is highly adaptive and innovative," said Sandrone. "As organizations identify new ways of working through the use of AI, they will also have an advantage in identifying and attracting the kinds of talent that will sustain these new working models, including successfully reskilling current staff to take on new, higher-value roles."
Gartner clients can read more in: Future of Supply Chain 2026: Reshaping for a Machine-Enabled Future (https://www.gartner.com/document-reader/document/7367430). Nonclients can learn more in: Future of Supply Chain (https://www.gartner.com/en/supply-chain/insights/future-of-supply-chain-2026).
Gartner is the World Authority on AI
Gartner is an indispensable partner to C-Level executives and technology providers as they implement AI strategies to achieve their mission-critical priorities. The independence and objectivity of Gartner insights provide clients with the confidence to make informed decisions and unlock the full potential of AI. Clients across the C-Level are using Gartner's proprietary AskGartner AI tool to determine how to leverage AI in their business. With more than 2,500 business and technology experts, 6,000 written insights, as well as more than 1,000 AI use cases and case studies, Gartner is the world authority on AI. More information can be found here.
* * *
About Gartner Supply Chain Symposium/Xpo
Gartner Supply Chain Symposium/Xpo is the world's most important gathering of CSCOs and supply chain executives. Explore how CSCOs predict disruptions, achieve visibility, and lead with AI and innovation. Gain insights from Gartner experts and peers on rethinking models, integrating technology and designing resilient, future-ready supply chains.
The next Gartner Supply Chain Symposium/Xpos will take place in:
Orlando: May 4-6
Barcelona: May 18-20
* * *
About the Gartner Supply Chain Practice
The Gartner Supply Chain Practice provides actionable, objective insights for supply chain leaders and their teams, so they can respond to disruption and innovate for the future through leading-edge supply chain management practices. Additional information is available at https://www.gartner.com/en/supply-chain. Follow news and updates from the Gartner Supply Chain Practice on LinkedIn and X using #GartnerSC. Visit the Gartner Supply Chain Newsroom for more information and insights.
* * *
Original text here: https://www.gartner.com/en/newsroom/press-releases/2026-02-25-gartner-survey-shows-55-percent-of-supply-chain-leaders-expect-agentic-ai-to-reduce-entry-level-hiring-needs
[Category: BizConsulting]
Consultants Marn-Ki Jeong and Ki-Soon Park and Attorney David K. S. Oh of Dentons Lee Analyze the Economic Impact of the Proposed Online Platform Fairness Act and Offer Regulatory Recommendations
WASHINGTON, Feb. 26 -- Dentons, a law firm, issued the following news:
* * *
Consultants Marn-Ki Jeong and Ki-Soon Park and Attorney David K. S. Oh of Dentons Lee analyze the economic impact of the proposed Online Platform Fairness Act and offer regulatory recommendations
Consultants Marn-Ki Jeong and Ki-Soon Park and Attorney David K. S. Oh of Dentons Lee delivered a keynote address and led designated panel discussions at the 82nd Industrial Development Forum hosted by the Korea Industrial Alliance Forum on January 29, 2026, at the Automobile Hall in Seocho-dong, Seoul. The forum was held under
... Show Full Article
WASHINGTON, Feb. 26 -- Dentons, a law firm, issued the following news:
* * *
Consultants Marn-Ki Jeong and Ki-Soon Park and Attorney David K. S. Oh of Dentons Lee analyze the economic impact of the proposed Online Platform Fairness Act and offer regulatory recommendations
Consultants Marn-Ki Jeong and Ki-Soon Park and Attorney David K. S. Oh of Dentons Lee delivered a keynote address and led designated panel discussions at the 82nd Industrial Development Forum hosted by the Korea Industrial Alliance Forum on January 29, 2026, at the Automobile Hall in Seocho-dong, Seoul. The forum was held underthe theme, "Regulation and the Economy - Economic Effects and Outlook upon the Introduction of the Online Platform Fairness Act. During the forum, the Dentons Lee speakers examined the economic implications of the proposed Online Platform Fairness Act and presented recommendations regarding its regulatory direction.
At the forum, discussions addressed the regulatory framework surrounding the introduction of the Online Platform Fairness Act, including ex ante regulation versus ex post enforcement, the impact on industrial competitiveness and employment, potential linkages with the U.S.-Korea trade environment, and changes in the global platform competitive landscape. Approximately 90 industry representatives and more than 20 media organizations attended the forum. The presentations were recorded and broadcast on KBS 1 Radio's Economic Seminar program.
Consultant Marn-Ki Jeong, in his keynote presentation, provided an estimated analysis indicating that, upon full implementation of the Online Platform Fairness Act, per capita GDP could decline by 12.6%, with cumulative economic losses over a ten-year period reaching up to USD 469 billion (approximately KRW 670 trillion). He further shared quantitative findings regarding the impact of introducing an opt-in requirement for targeted advertising on production and employment, emphasizing the need for policy design that takes into account Korea's industrial structure and the current level of platform self-reliance. In addition, he noted that, rather than uniformly adopting an ex ante regulatory model such as the European Union's Digital Markets Act, consideration should be given to an ex post approach grounded in the competition law framework.
Consultant Ki-Soon Park observed that, in light of Korea's highly digital-dependent economic structure, excessive ex ante regulation may constrain the innovation ecosystem. He further noted that, amid intensifying competition between U.S. and Chinese platform companies in the global marketplace, regulatory measures that limit the growth capacity of domestic enterprises could, as a practical matter, increase the likelihood of market expansion by foreign platforms. He also emphasized that regulatory structures effectively targeting companies of a particular country could potentially escalate into U.S.-Korea trade issues, underscoring the importance of a balanced policy design that comprehensively considers industrial competitiveness as well as the broader diplomatic and trade environment.
Attorney David K. S. Oh noted that introducing an EU-style ex ante regulatory regime without sufficient review of Korea's domestic industrial structure could dampen innovation drivers and investment incentives. He explained that, while the European Union adopted the Digital Markets Act in the absence of homegrown global Big Tech companies, Korea operates in a different policy environment, given that it maintains a number of competitive local platform companies. He further referenced prior instances in which the platform market was reshaped through continuous technological innovation rather than through uniform regulatory intervention. In that context, he suggested that, instead of imposing broad ex ante prohibitions on specific business practices, a phased and carefully calibrated regulatory framework grounded in a comprehensive impact assessment of the overall industry ecosystem would be more appropriate.
Dentons Lee provides counsel to clients seeking to proactively respond to policy developments and systematically manage legal and regulatory risk, drawing on its domestic and international experience and global network in the areas of platform regulation, antitrust and competition law, and data and trade regulation.
Press Coverage:
"Online Platform Fairness Act Could Cut Per Capita GDP by 12.6%, While Chinese Platforms Stand to Benefit"
Yonhap News Agency
"A Policy Misstep Over Coupang Should be Avoided. Online Platform Fairness Act Could Reduce Korea's GDP by 12.6%"
Edaily
* * *
About Dentons
Redefining possibilities. Together, everywhere. For more information visit dentons.com
* * *
Marn-Ki Jeong
Consultant
Seoul
* * *
Ki-Soon Park
Consultant
Seoul
* * *
David K. S. Oh
Attorney (Admitted to Singapore Bar)
Seoul
* * *
Original text here: https://www.dentonslee.com/en/about-dentons-lee/news/2026/february/consultants-marn-ki-jeong-and-ki-soon-park-and-attorney-david-k-s-oh-analyze-the-economic-impact
[Category: BizLaw/Legal]
Bepirovirsen Accepted for Regulatory Review in Japan as a Potential First-In-Class Treatment for Chronic Hepatitis B
LONDON, England, Feb. 26 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:
* * *
Bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B
- Submission supported by statistically significant and clinically meaningful functional cure rates demonstrated in pivotal phase III B-Well trials
- Nearly 1 million people in Japan live with chronic hepatitis B1, a leading cause of liver cancer2
- First regulatory filing globally, with SENKU designation enabling expedited review3
*
GSK plc
... Show Full Article
LONDON, England, Feb. 26 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:
* * *
Bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B
- Submission supported by statistically significant and clinically meaningful functional cure rates demonstrated in pivotal phase III B-Well trials
- Nearly 1 million people in Japan live with chronic hepatitis B1, a leading cause of liver cancer2
- First regulatory filing globally, with SENKU designation enabling expedited review3
*
GSK plc(LSE/NYSE: GSK) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted for review a new drug application (NDA) for bepirovirsen, an investigational antisense oligonucleotide (ASO), for the treatment of adults with chronic hepatitis B (CHB).
Chronic hepatitis B is a major public health challenge, affecting more than 250 million people worldwide and nearly one million people in Japan./1 The current standard of care - nucleos(t)ide analogues - often requires lifelong therapy and the functional cure rates remain low, typically only 1%. Functional cure occurs when the hepatitis B virus DNA and viral protein - hepatitis B surface antigen (HBsAg) - are at levels low enough to be undetectable in the blood for at least 24 weeks after stopping all treatment, and can be controlled by the immune system without medication. Functional cure is associated with significant reduction in the risk of long-term liver complications, including liver cancer. It is estimated that ~56% of liver cancer cases globally are caused by CHB./2
The regulatory submission is supported by positive results from the B-Well 1 and B-Well 2 Phase III trials, where bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate. Functional cure rates were significantly higher with bepirovirsen plus standard of care compared with standard of care alone across all ranked endpoints, including in patients with lower baseline HBsAg levels where an even greater effect was observed. Bepirovirsen demonstrated an acceptable safety and tolerability profile consistent with previous studies. The data are anticipated to be presented at a congress and submitted for scientific peer-reviewed publication in 2026.
Bepirovirsen was granted SENKU designation in Japan/3 in August 2024, reflecting its innovation and potential to address a disease with high unmet medical need. SENKU designation is intended to facilitate early patient access through an expedited regulatory review process.
Clinical trial programme
B-Well 1 [NCT05630807] and B-Well 2 [NCT 05630820] trials are global multi-centre, randomised, double-blind, placebo-controlled trials conducted in 29 countries. They assessed the efficacy, safety, pharmacokinetic profile, and the durability of functional cure in nucleos(t)ide analogue (NA)-treated in non-cirrhotic participants with CHB and baseline surface antigen (HBsAg) 3000 IU/ml. The primary endpoint assessed the proportion of participants achieving functional cure in patients with baseline surface antigen (HBsAg) 3000 IU/ml. A key ranked secondary endpoint evaluated functional cure in patients with baseline HBsAg 1000 IU/ml.
* * *
About chronic hepatitis B
Hepatitis B is a viral infection that can cause both acute and chronic liver disease. Chronic hepatitis B occurs when the immune system is unable to clear the virus, resulting in long-lasting infection that affects more than 250 million people worldwide. The disease causes approximately 1.1 million deaths each year , and approximately 4000 deaths in Japan annually./1 Many patients often require lifelong antiviral therapy for viral suppression; making functional cure a critical goal in disease management.
* * *
About bepirovirsen
Bepirovirsen is a triple action investigational antisense oligonucleotide (ASO), designed to recognise and orchestrate the destruction of the genetic components (i.e. mRNA and pregenomic RNA) of the hepatitis B virus that can lead to chronic disease, potentially allowing a person's immune system to regain control. Bepirovirsen inhibits the replication of the viral genome in the body, suppresses the level of hepatitis B surface antigen (HBsAg) in the blood, and stimulates the immune system to increase the chances of a durable and sustained response.
Bepirovirsen is also being evaluated as a potential backbone therapy for future sequential treatment strategies aimed at expanding functional cure to broader patient populations.
GSK licensed bepirovirsen from Ionis and collaborated with them on its development. Bepirovirsen has been recognised by global regulatory authorities for its innovation and potential to address significant unmet need in hepatitis B, with Fast Track designation from the US FDA, Breakthrough Therapy designation in China and SENKU designation in Japan. Bepirovirsen is currently not approved anywhere in the world.
* * *
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
* * *
References
1./ Polaris Observatory Dashboard. Available at https://cdafound.org/polaris/dashboard/ (last accessed January 2026).
2./ Rumgay H et al . Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598-1606. doi: 10.1016/j.jhep.2022.08.021
3./ GSK Press release, Bepirovirsen granted SENKU designation in Japan for chronic hepatitis B, August 2024. Available at: https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-granted-senku-designation-in-japan-for-chronic-hepatitis-b/. (last accessed: January 2026).
4./ Slaets, L. et al. "Systematic review with meta-analysis: hepatitis B surface antigen decline and seroclearance in chronic hepatitis B patients on nucleos(t)ide analogues or pegylated interferon therapy" in GastroHep 2, 106-116 (2020)
5./ EASL, "Clinical Practice Guidelines on the management of hepatitis B virus infection" in Journal of Hepatology Volume 83, Issue 2, August 2025, Pages 502-583. Available at: https://www.sciencedirect.com/science/article/pii/S0168827825001746 (last accessed: January 2026).
6./ GSK Press release, GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B, January 2026. Available at: https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-b-well-1-and-b-well-2-phase-iii-trials-for-bepirovirsen-a-potential-first-in-class-treatment-for-chronic-hepatitis-b/. (last accessed: January 2026).
7./ WHO. Global hepatitis report 2024. Available at: https://www.who.int/publications/i/item/9789240091672 (last accessed: January 2026).
* * *
Original text here: https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-accepted-for-regulatory-review-in-japan/
[Category: BizPharmaceuticals]
